Shani Shilo
Member of Advisory Committee
Dr. Shani Shilo is a leading advocate, researcher, and healthcare innovator dedicated to improving outcomes for people living with lung cancer. She founded Israel’s first national lung cancer patient advocacy organization in 2014, following her husband’s diagnosis with stage IV lung cancer at age 43. Identifying profound gaps in support and awareness, she built a nationwide network offering patient and caregiver communities, mental health support, mentoring, public awareness campaigns, and accessible scientific information. Her work has transformed the landscape of patient advocacy and has supported thousands of families across Israel.
Dr. Shilo holds a Doctor of Dental Medicine (DMD) and a PhD in biochemistry from the Hebrew University of Jerusalem. She completed postdoctoral research at The Ohio State University Medical Center, focusing on tissue repair and angiogenesis, and was awarded the Heart and Lung Institute’s Distinguished Postdoctoral Award. Prior to her advocacy leadership, she directed R&D initiatives in the biotechnology sector, specializing in tissue regeneration technologies.
She led national efforts to integrate lung cancer screening into Israel’s healthcare system, culminating in the launch of the national screening program that started in 2025. Internationally, she served as the Chair of the Patient Advocates Committee at the International Association for the Study of Lung Cancer (IASLC), years 2023-2025 and advises global pharmaceutical companies on patient-centered strategy.
Dr. Shilo joined the Advisory Committee of FairLife Lung Cancer Care in October 2025.
